n a potentially significant policy shift, the Food and Drug Administration plans to stop redacting portions of the resumes submitted by scientific and medical experts who serve on its advisory committees.

The change comes in response to a lawsuit that was filed last year by Public Citizen, a consumer advocacy group, which argued the redactions were unlawful and robbed the public of the opportunity to understand the extent to which any of the expert advisors may have conflicts.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy